Compare Stocks: STOK, PCVX, APGE, and IMVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.55 +0.1%	$123.46	$35.39 ▼ $134.88	$8.37B	0.34	1.66 million shs	1.48 million shs
IMVT Immunovant	$41.82	$37.98	$14.47 ▼ $42.92	$8.64B	0.77	1.54 million shs	722,453 shs
PCVX Vaxcyte	$58.07 -1.3%	$54.73	$29.87 ▼ $65.00	$8.64B	1.23	1.41 million shs	656,559 shs
STOK Stoke Therapeutics	$31.27 -0.1%	$30.67	$16.90 ▼ $40.22	$2.02B	1.2	753,159 shs	495,115 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-0.07%	-0.03%	+0.37%	+65.70%	+259.76%
IMVT Immunovant	-1.83%	+5.23%	+7.87%	+52.13%	+163.18%
PCVX Vaxcyte	-1.32%	-0.05%	+4.71%	+12.35%	+86.56%
STOK Stoke Therapeutics	-5.03%	-1.94%	+7.48%	+4.09%	+85.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.55 +0.1%	$123.46	$35.39 ▼ $134.88	$8.37B	0.34	1.66 million shs	1.48 million shs
IMVT Immunovant	$41.82	$37.98	$14.47 ▼ $42.92	$8.64B	0.77	1.54 million shs	722,453 shs
PCVX Vaxcyte	$58.07 -1.3%	$54.73	$29.87 ▼ $65.00	$8.64B	1.23	1.41 million shs	656,559 shs
STOK Stoke Therapeutics	$31.27 -0.1%	$30.67	$16.90 ▼ $40.22	$2.02B	1.2	753,159 shs	495,115 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-0.07%	-0.03%	+0.37%	+65.70%	+259.76%
IMVT Immunovant	-1.83%	+5.23%	+7.87%	+52.13%	+163.18%
PCVX Vaxcyte	-1.32%	-0.05%	+4.71%	+12.35%	+86.56%
STOK Stoke Therapeutics	-5.03%	-1.94%	+7.48%	+4.09%	+85.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.20	Hold	$124.43	-7.52% Downside
IMVT Immunovant	2.50	Moderate Buy	$44.00	5.21% Upside
PCVX Vaxcyte	2.50	Moderate Buy	$86.00	48.10% Upside
STOK Stoke Therapeutics	2.73	Moderate Buy	$43.00	37.51% Upside

Current Analyst Ratings Breakdown

Latest STOK, PCVX, APGE, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	APGE Apogee Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$81.00 ➝ $135.00
8/12/2026	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/12/2026	PCVX Vaxcyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	STOK Stoke Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/4/2026	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$47.00 ➝ $50.00
8/4/2026	STOK Stoke Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/4/2026	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$38.00 ➝ $40.00
8/4/2026	STOK Stoke Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$60.00 ➝ $58.00
8/4/2026	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
7/29/2026	IMVT Immunovant	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/17/2026	APGE Apogee Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.23 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$3.56 per share	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$18.53 per share	N/A
STOK Stoke Therapeutics	$184.42M	10.94	N/A	N/A	$5.36 per share	5.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-32.16%	-30.91%	N/A
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	N/A
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	N/A
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	N/A

Latest STOK, PCVX, APGE, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million
5/20/2026	Q4 2026	IMVT Immunovant	-$0.60	-$0.73	-$0.13	-$0.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	32.59	32.59
IMVT Immunovant	N/A	7.27	7.27
PCVX Vaxcyte	N/A	5.72	5.72
STOK Stoke Therapeutics	N/A	7.69	7.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
IMVT Immunovant	47.08%
PCVX Vaxcyte	96.78%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
IMVT Immunovant	1.90%
PCVX Vaxcyte	3.30%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
IMVT Immunovant	120	206.55 million	202.63 million	Optionable
PCVX Vaxcyte	160	148.80 million	143.89 million	Optionable
STOK Stoke Therapeutics	100	64.53 million	58.33 million	Optionable

STOK, PCVX, APGE, and IMVT Headlines

Recent News About These Companies

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript

August 11 at 7:49 AM | finance.yahoo.com

The Manufacturers Life Insurance Company Purchases 55,672 Shares of Stoke Therapeutics, Inc. $STOK

August 9, 2026 | marketbeat.com

Stoke Therapeutics, Inc. $STOK Shares Acquired by Assenagon Asset Management S.A.

August 9, 2026 | marketbeat.com

Research Analysts Offer Predictions for STOK Q3 Earnings

August 8, 2026 | americanbankingnews.com

Stoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

HC Wainwright Has Bearish Forecast for STOK FY2029 Earnings

August 7, 2026 | americanbankingnews.com

Q3 EPS Estimates for Stoke Therapeutics Cut by HC Wainwright

August 6, 2026 | marketbeat.com

Barry Ticho Sells 7,176 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

August 6, 2026 | insidertrades.com

Wedbush Increases Stoke Therapeutics (NASDAQ:STOK) Price Target to $40.00

August 6, 2026 | americanbankingnews.com

Canaccord Genuity Group Issues Pessimistic Forecast for Stoke Therapeutics (NASDAQ:STOK) Stock Price

August 6, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from Chardan Capital

August 6, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells $208,391.04 in Stock

August 5, 2026 | marketbeat.com

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

August 5, 2026 | seekingalpha.com

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

August 5, 2026 | finance.yahoo.com

Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)

August 5, 2026 | theglobeandmail.com

Stoke Therapeutics, Inc. Q2 2026 Earnings Call Summary

August 5, 2026 | finance.yahoo.com

FY2029 Earnings Estimate for STOK Issued By HC Wainwright

August 5, 2026 | marketbeat.com

Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOK

August 5, 2026 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Guggenheim

August 4, 2026 | marketbeat.com

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings

August 4, 2026 | 247wallst.com

Stoke outlines rolling NDA in Q1 2027 as $420M cash supports potential U.S. launch by early 2028

August 4, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, PCVX, APGE, and IMVT Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$134.55 +0.10 (+0.07%)

Closing price 04:00 PM Eastern

Extended Trading

$134.57 +0.02 (+0.01%)

As of 04:30 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Immunovant NASDAQ:IMVT

$41.82 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$41.83 +0.01 (+0.02%)

As of 04:15 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Vaxcyte NASDAQ:PCVX

$58.07 -0.79 (-1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$58.07 0.00 (0.00%)

As of 04:43 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Stoke Therapeutics NASDAQ:STOK

$31.27 -0.04 (-0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$31.28 +0.02 (+0.05%)

As of 04:15 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STOK, PCVX, APGE, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STOK, PCVX, APGE, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STOK, PCVX, APGE, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, PCVX, APGE, and IMVT Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Immunovant NASDAQ:IMVT

Vaxcyte NASDAQ:PCVX

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STOK, PCVX, APGE, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STOK, PCVX, APGE, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STOK, PCVX, APGE, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, PCVX, APGE, and IMVT Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Immunovant NASDAQ:IMVT

Vaxcyte NASDAQ:PCVX

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools